The beneficial effect of palliative resection in metastatic colorectal cancer

Jh, Park; Ty, Kim; Kh, Lee; Han, Shiyu; Oh, Do‐Youn; Im, Sungbin; Kang, Gyeong Hoon; Chie, Eui Kyu; Ha, Sang Keun; Sy, Jeong; Kj, Park

doi:10.1038/bjc.2013.94

Cited by 48 publications

(38 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our figures also highlight the fact that relatively few patients undergo surgical resection of their metastatic disease. Median overall survival has been shown to be significantly improved with complete or macroscopically clear resection margins of CRCLMPM compared with palliative chemotherapy, [20] as well as resection of the primary CRC only in stage IV disease. [21] …”

Section: Crcpmmentioning

confidence: 99%

Colorectal cancer in South Africa: An assessment of disease presentation, treatment pathways and 5-year survival

Brand

Gaylard²,

Ramos

2018

S Afr Med J

View full text Add to dashboard Cite

Section: Crcpmmentioning

confidence: 99%

Colorectal cancer in South Africa: An assessment of disease presentation, treatment pathways and 5-year survival

Brand

Gaylard²,

Ramos

2018

S Afr Med J

View full text Add to dashboard Cite

“…Approximately 1 in 5 patients with CRC present with distant metastatic disease at diagnosis and the distant metastases, such as to the liver or lung, are the major cause of death. A significant proportion of patients with metastatic CRC are not curable; however, a subset of these patients with liver-and/or lung-isolated disease is potentially curable with surgery (2)(3)(4).…”

Section: Introductionmentioning

confidence: 99%

Clinicopathological characteristics and prognosis of stage IV colorectal cancer

Miyoshi

Ohue

Shingai

et al. 2015

Molecular and Clinical Oncology

View full text Add to dashboard Cite

The aim of this study was to determine the role of curative resection in metastatic colorectal cancer (CRC) and determine the subset of patients who may benefit from concurrent curative resection of primary and metastatic lesions. A total of 103 patients diagnosed with synchronous liver and/or lung metastatic CRC at the Osaka Medical Center for Cancer and Cardiovascular Diseases between 1983 and 2010 were retrospectively investigated. All the patients underwent curative resection of the primary and metastatic lesions. The median follow-up time was 5.69 years. A total of 83 and 13 patients had only liver or lung metastasis, respectively, whereas 7 patients had synchronous liver and lung metastases. A total of 25 patients (24.2%) had no recurrence following curative resection and 14 patients (13.5%) received more than one re-resection for disease recurrence and survived without any further recurrence thereafter. The 5-year survival of liver or lung metastatic CRC was 43.7 or 90.0%, respectively. However, the median overall survival (OS) in patients with synchronous liver and lung metastases was 20.7 months. In the univariate and multivariate analyses, tumour invasion, synchronous liver and lung metastases and time-to-recurrence after the first curative resection were significantly associated with OS and disease-free survival. In conclusion, curative resection confers longer-term survival in patients with liver or lung metastatic CRC.

show abstract

“…Approximately, 25% of patients with CRC present with liver metastasis at the initial diagnosis or will develop liver metastasis during the course of their disease (Chow and Chok, 2019). In spite of the emergence of highly effective chemotherapy and advances in surgical techniques, the pool of patients with liver and/or lung-isolated metastasis has expanded and for the majority of patients with metastatic CRC (mCRC), the treatment remains a clinical challenge (Park et al, 2013). Indeed, for many years 5-fluorouracil (FU)based regimens has been the backbone of systemic therapy for mCRC.…”

Section: Introductionmentioning

confidence: 99%

Systemic therapy as First-Line Treatment for Patients with Metastatic Colorectal Cancer: A Systematic Review and Network meta-analysis of Randomized Clinical Trials

Xu¹,

Sak²,

Erol³

2020

Preprint

View full text Add to dashboard Cite

Purpose: To assess the relative efficacy and safety of first-line systemic therapies in patients with metastatic CRC (mCRC).Experimental Design: A comprehensive literature review was conducted including MEDLINE, Embase, and the Cochrane Central Registry of Controlled Trials for phase II or III Randomized Controlled Trials (RCTs) published up to and including July 15, 2019.We included RCTs in which at least 1 intervention was either a chemotherapeutic agents (such as, fluorouracil, irinotecan, or oxaliplatin) or antibodies targeting angiogenesis (such as, bevacizumab) or agents that act on the epidermal growth factor receptor pathway (such as, cetuximab and panitumumab) or studies reported at least one of the following outcomes: Overall Survival (OS), Progression-Free Survival (PFS) and/or serious adverse events (SAEs). Using a random effect model, we performed a Bayesian network meta-analysis to analyze the probability of optimal therapeutic regime obtained from direct comparisons with indirect evidences. We estimated hazard ratios (HRs) for OS and PFS.Results: A total of 30 RCTs comprising (12, 146 patients with mCRC comparing 25 different strategies were included. The triple combination FOLFOXIRI [fluorouracil, leucovorin, oxaliplatin, and irinotecan] plus bevacizumab provided significant survival benefits with improved OS over all other treatments. The network meta-analysis also indicated a significant advantage of using FOLFOXIRI plus bevacizumab in comparison to other treatment strategies for PFS. Besides, FOLFOXIRI plus bevacizumab was associated with the lowest risk of serious adverse events.Conclusions: Our study supported the use of FOLFOXIRI plus bevacizumab as the best first-line regimen and potentially effective and safe strategy for the management of patients with mCRC.

show abstract

The beneficial effect of palliative resection in metastatic colorectal cancer

Cited by 48 publications

References 23 publications

Colorectal cancer in South Africa: An assessment of disease presentation, treatment pathways and 5-year survival

Colorectal cancer in South Africa: An assessment of disease presentation, treatment pathways and 5-year survival

Clinicopathological characteristics and prognosis of stage IV colorectal cancer

Systemic therapy as First-Line Treatment for Patients with Metastatic Colorectal Cancer: A Systematic Review and Network meta-analysis of Randomized Clinical Trials

Contact Info

Product

Resources

About